Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Drug supplies dwindle as COVID-19 crisis continues

By Brian Buntz | October 23, 2020

coronavirus COVID-19

[Photo by Fusion Medical Animation on Unsplash]

COVID-19-related drugs are in short supply in the U.S., according to a recent report from the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota.

Supplies are scarce for nearly three-quarters (72.5% or 29 of 40) of COVID-19 drugs, according to the CIDRAP report, which cites data from the American Society of Health-System Pharmacists (ASHP).

FDA, which has stricter criteria for drug shortages, has concluded that supplies are in short supply for 18 of 40 drugs.

CIDRAP concluded that, by either measure, drug supplies have fallen to “unacceptable” levels. Drug treatments for the novel coronavirus experiencing shortages according to ASHP data include:

  • Propofol
  • Albuterol
  • Midazolam
  • Hydroxychloroquine
  • Fentanyl
  • Azithromycin
  • Morphine

The COVID-19 pandemic has led to shortages of a variety of drugs and active pharmaceutical ingredients, especially for those made in India and China. A surge of interest in hydroxychloroquine and chloroquine as potential COVID-19 treatments earlier this year also led to a severe shortage of those drugs. FDA granted — and later revoked —  emergency use authorization for those drugs.

U.S. drug shortages are not a new problem, however. CIDRAP has tracked deficits of critical drugs since its founding in 2001. The emergence of COVID-19, however, has worsened the situation through factory closures and supply chain disruptions.

“Drug shortages can be a matter of life and death, and some shortages mean that a life-saving drug is not available to U.S. patients at any price,” CIDRAP concluded in a statement.

CIDRAP made several recommendations to address the problem, including investing in national infrastructure to analyze, predict and manage shortages of essential medicines.

Tell Us What You Think! Cancel reply

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards